[The effects of different PAP domains on hepatitis B virus replication]

Zhonghua Gan Zang Bing Za Zhi. 2010 Feb;18(2):105-8. doi: 10.3760/cma.j.issn.1007-3418.2010.02.007.
[Article in Chinese]

Abstract

Objective: To investigate the effects of different PAP domains on hepatitis B virus replication.

Methods: The full length and two truncated PAP mutants were cloned into a eukaryotic expression plasmid, and were transfected into HepG2.2.15 cells using lipofectamine 2000. 3 days after transfection, the medium and cells were collected. HBsAg and HBeAg were measured using ELISA. The titers of HBV DNA were quantified using fluorogenic quantitative PCR (FQ-PCR). HepG2 cells were used to determine the cytotoxicity of the plasmids transfection by MTT assays.

Results: The inhibitory effect on HBV replication of the C-terminal 25 amino acids deleted PAP mutant (pXF3H-PAP14) was not significantly different from that of the full length PAP (pXF3H-PAP12) (Chi-square test = 0.5, 2.0, 0.02, probability value more than 0.05), however, the cytotoxicity of pXF3H-PAP14 was lower than that of pXF3H-PAP12 (Chi-square test = 7.7, probability value less than 0.01). Both N-terminal 69 amino acids deleted mutant and C-terminal 25 amino acids deleted mutant had no cytotoxicity and no antiviral activity.

Conclusion: C-terminal 25 amino acid of PAP is related to cytotoxicity but not related to antiviral activity of PAP. N-terminal 69 amino acid of PAP is related to the anti-HBV effect of PAP.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antiviral Agents / pharmacology*
  • Blotting, Western
  • DNA, Viral / drug effects
  • DNA, Viral / metabolism
  • Hep G2 Cells
  • Hepatitis B Surface Antigens / metabolism
  • Hepatitis B e Antigens / metabolism
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / genetics
  • Hepatitis B virus / physiology*
  • Humans
  • Liposomes
  • Plasmids / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribosome Inactivating Proteins, Type 1 / genetics*
  • Ribosome Inactivating Proteins, Type 1 / metabolism
  • Ribosome Inactivating Proteins, Type 1 / pharmacology*
  • Sequence Deletion
  • Transfection
  • Virus Replication / drug effects*

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Liposomes
  • Ribosome Inactivating Proteins, Type 1
  • pokeweed antiviral protein